IVN201 enters Ph I trial as ImVisioN completes $4.1M series A financing

ImVisioN Therapeutics AG, a Swiss biopharmaceutical company pioneering intralymphatic immunotherapy, has enrolled the first patient in a Phase I study of its lead product candidate IVN201, an immunotherapeutic therapy for cat dander allergy.

The Muttenz-based firm also announced the closing of a series A financing round of 4.6 million Swiss francs ($4.1 million), allowing the clinical development of IVN201. The financing round was led by Aravis Venture Associates AG and involved the participation of the founding investor Nextech Venture and private individuals.

The primary objective of this first human clinical study of ImVisioN's lead product IVN201 for the treatment of cat dander allergies will be product safety, but the study will also assess several efficacy parameters. The first patient has been enrolled for this placebo-controlled, double-blind trial, conducted at the University Hospital in Zurich, Switzerland. The study will include a total of 20 patients allergic to cat dander and is expected to complete in the second quarter of 2009.